AI models need more data about biology, and OpenAI is paying to create it

OpenAI is launching an initiative to acquire data from failed biotech companies, specifically targeting regulatory filings and manufacturing records from bankruptcy proceedings. This project seeks to improve the performance of AI models in the medical and biological fields by utilizing high-quality clinical data that is otherwise difficult to access. By securing these records, the company aims to address a critical scarcity of specialized information required to train more effective healthcare and life sciences tools.